Article Abstract

Target blood pressure and cardiovascular risk

Authors: Céline Dreyfuss-Tubiana, Philippe Sosner, Jacques Blacher


An article recently published in the Lancet (1) concerned a meta-analysis of two therapeutic trials ONTARGET (2) and TRANSCEND (3). They were both designed to compare angiotensin receptor blocker (ARB) to angiotensin-converting enzyme (ACE) inhibitors (or their combination) or placebo respectively, to reduce the rate of a composite of cardiovascular death, myocardial infarction (MI), stroke and hospital admission for heart failure, among patients at high risk for cardiovascular events.